Seres Therapeutics, Inc.·4

Jul 18, 4:58 PM ET

Aunins John G. 4

4 · Seres Therapeutics, Inc. · Filed Jul 18, 2018

Insider Transaction Report

Form 4
Period: 2018-07-16
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
  • Sale

    COMMON STOCK

    2018-07-15$8.10/sh14,279$115,726160,927 total
Footnotes (2)
  • [F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2018.
  • [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $7.82 to $8.60. The Reporting Persons undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION